What a great week for Geron

Geron closed up 13 cents to close at $2.76 on 1.9 million shares. The three month avg. volume is 894,148 shares. Geron was at $1.71 on Aug 15th what a great run on no news. Sept 5th at 10:55AM Chip the CEO will speak. It will be webcast. I'm hoping for good news. We will see. The secondary offering is a worry,[if there is one] I got burned on the last one. That's why I sold some covered calls just in case.

ACTC closed down a little at 0.0803 on 2.6 million shares. The three month avg. volume is 5 million shares.

AAPL closed up a little at $665.24 on 11.4 million shares. The three month avg. volume is 13.8 million shares.

Good luck in this rigged casino,

Geron up big again

Geron closed up 22 cents at $2.63 on 3.4 million shares. The three month avg. volume is 849,533 shares.
Geron to present at the Stifel Nicolaus Healthcare Conference Sept. 5 Wed. at 10:55AM.  This will be very interesting. If Chip the CEO says anything new and good, we go over $3. If it's more of the same we head slowly to $2.

Good luck in this rigged casino,

Geron up 24 cents pre-market wow

Geron  shares rose 11%. Stifel Nicolaus analysts started the biotech company with a buy rating on Thursday morning. Target $4.
Up 24 cents just on a upgrade. My almost 9,000 shares love it. My 4,000 covered shares do not, but that's ok. We still need news, by all the signs it should be good. BUT I've been doing this for 40 years, it still could be a pump and dump, a secondary offering is coming.

Good luck in this rigged casino,

Sienna's telomerase based Cancer diagnostics test kit

• Everyone knows about the Imetelstat trial results but few know about the large scale testing of Sienna's telomerase based Cancer diagnostics test kit. The results of the testing is expected in December. The pre large scale testing results were the test was 97% effective at catching cancer early and there were no false positives for this non invasive test kit. Many do not also know Geron is Sienna Cancer Diagnostics largest share holder.

  This would be great for Geron, they would get more income from the selling of the Cancer diagnostics test kits through royalties and the increase in Sienna's value.

  Geron closed down 3 cents at $2.41 on 1,379,886 shares. The three month avg, is 849,533 shares. Still with no real news we should go a little lower, maybe $2.10.

  
  

  ACTC was down a little at 0.08 on 1.8 million shares. The three month avg. is 5 million shares. Waiting for news.

  
  

  AAPL closed down just a little at $673.47 on 7.2 million shares. The three month avg. volume is 13.9 million shares. Still the best company out there.

  
  

  Good luck in this rigged casino,

GRN1005 trials updated yesterday on Clinical Trials . gov

Geron has added more sites for its GRN1005 trials. It's all good. I'm surprised the price is still around $2.40. Still think we go to $2.10 with no real news on results of Phase 2 trials.

Good luck in this rigged casino,

Geron up big again

Geron closed up 14 cent at $2.44 on 1.3 million shares. The three month avg. volume is 832,770 shares. Why the run from $1.71 on Aug. 15th to $2.55 on Aug 28th? I have no real answer, I sold 40 covered calls at different prices and months just because the run may be all bs. Why? Geron needs money they will do secondary offering soon. The last one I lost half my money on.  JPM made 50 cents a shares selling the offering. At $1.71 a share they would have to sell the secondary at $1.50 or less a share, with JPM fees that would leave Geron with $50 million or less [that's if they sold 50 million, they have the ok to sell 100 million shares] So I think they are going for $2.50 a share. That would mean a run to $3 plus, then a secondary offering at $2.50 a share, maybe 100 million shares. That would $200 million clear and would do Phase 3 with the help of a partner.  That's my guess on the run, I hope [with my 9,000+ uncover shares] I'm wrong.
We will see.

ACTC closed down a little but still above 8 cents at 0.0808 on 2.3 million shares. The three month avg. volume is 5 million shares. Need god news.

AAPL give back a little to close at $674.80 on 9.4 million shares. The three month avg. volume is 14.1 million shares.

Good luck in this rigged casino,

ACTC up over 8

ACTC closed at 0.0809 on 4.9 million shares. The three month avg. volume is 4.9 million shares.

AAPL up  big to close at $675.68 on 15.1 million shares. The three month avg. volume is 14.1 million shares. We go higher.

Geron closed flat at $2.30 on 1.4 million shares. The three month avg. volume is 812,400 share. With the good article on Seeking Alpha today, you would think Geron would be up. I think we go down to $2.10 soon if there is no more good news. Will buy back my Oct $2 calls if it does.

Good luck in this rigged casino,

Geron good article Seeking Alpha

This was in Seeking Alpha today: Consider These 3 Biotech Stocks for Potential Growth.
Geron was established in 1990 and completed its IPO in 1996. It is unusual to see a biotech company which has survived for that length of time without a product on the market. Most biotech companies in this position either fail or get acquired. Geron started out by focusing on stem cell treatments as well as oncology treatments, but decided to abandon stem cell research in 2011 due to the high cost of working on both, and decided to focus solely on oncology. It is working on the disposal of its stem cell assets, but there has been no progress reported so far. The company has two oncology drugs under development which have the potential to revolutionize cancer treatment if they are successful. The company has six Phase 2 trials currently underway.
The company's first, and most advanced drug, is called Imetelstat, a telomerase inhibitor which is currently in Phase 2 trials. Telomerase is the enzyme that enables cells to divide indefinitely without becoming unstable, thus allowing tumors to grow. There is plenty of scientific evidence to indicate that the enzyme is a key factor in the development of cancer. Geron is not the only company working on telomerase inhibitors, but it is the most advanced. Its strategy for cancer treatment is to stop or inhibit the growth of tumors. Imetelstat is currently in trials for the treatment of four different types of cancer, including breast cancer, NSCLC (non-small cell lung cancer) for solid tumors, multiple myeloma, and essential thrombocythemia for malignancies related to hematology. The data from all four trials is expected to become available over the next twelve months.
GRN1005 is an LRP-directed peptide drug combination aimed at treating brain cancer, which is currently very difficult to treat, because existing cancer drugs cannot penetrate the barrier between circulating blood in the body and the fluids of the brain. GRN1005 uses the LRP-1 transport mechanism, which uses a particular protein to bypass the blood-brain barrier and deliver cancer drugs to the brain. GRN1005 is now in Phase 2 trials to test the effectiveness of treatment in breast and lung cancer that has spread to the brain.
Geron's approach to oncology is unique, and positive results from any of the trials could potentially boost the price of the stock. Conversely, there is also limited protection for the stock price because of the number of trials that are in progress simultaneously. Additionally, failure in one trial may be construed as a possible failure in other trials utilizing the same drug which could be catastrophic for the share price. I urge risk tolerant investors interested in Geron to conduct further research and be prepared to hold for twelve months or longer.

I've beed staying this for months. If Geron hits I'm rich if they miss, it's work till I drop.

Good luck in this rigged casino,

Gary Rabin ACTC's CEO Comments

MARLBOROUGH, Mass., Aug 27, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT")(ACTC, Trade ), a leader in the field of regenerative medicine, today issued a statement on the U.S. Appeals Court's ruling, upholding a lower court's dismissal of the case, "Sherley v. Sebelius," 11-5241, U.S. Court of Appeals for the District of Columbia Circuit (Washington), on the permissibility of federal funding of embryonic stem cell research.
"This court ruling should be of considerable benefit to ACT and our embryonic stem cell-based clinical programs," commented Gary Rabin, chairman and CEO. "It effectively removes major speed bumps for the National Institutes of Health (NIH) in terms of approving the several stem cell lines that we have submitted for their consideration for funding. With Friday's decisive ruling, we expect that a number of our embryonic stem cell lines will be approved for funding in coming months."
"Sherley v. Sebelius" had sought to block the United States Health and Human Services Department and the NIH from spending federal funds for research with hESCs, contending that doing so would violate the Dickey-Wicker Amendment, a short rider attached to legislation passed in 1996.
"This ruling removes a great deal of the ambiguity that has hampered legislative attempts to provide an efficient mechanism for federal funding of hESC research," continued Mr. Rabin. "The path for legislators to enact such legislation has now been cleared, and in that case we are optimistic that there could be encouraging new developments in the legislative arena, as well, in coming months. We would certainly hope that our patented, proprietary 'embryo-safe' single-cell blastomere technique would be a part of any such conversation. We feel that if we could educate more Americans about this technique, and how directly and effectively it addresses the various ethical objections to hESC research, that broad support for the technique and the field overall would quickly fall into place."
More commentary on Friday's court ruling will be posted today on Mr. Rabin's Chairman's blog.

Good news, up just a little, maybe we close above 8 cents.

AAPL looks great.

Geron giving back a little.

Good luck in this rigged casino,

Geron up 23 cents on 2.4 million shares

A great day for Geron up 11% to close at $2.30 on 2.4 million shares. The three month avg. volume is 786,725 shares. I wonder if this is MMs like JPM running the price up so they can make a killing when they sell a secondary offering. Selling [or buying calls] on the way up and shorting on the when down when they do the secondary offering, we all know is coming. Just wonder, because there is no news.

ACTC was up just a little to close at 0.0780 on 3.9 million shares. The three month avg. volume is 4.9 million shares. Need good news.

AAPL up 59 cents to close at $663.22 on 15.2 million shares. The three month avg. volume is 14.1 million shares. AAPL won it's patent case and was up $11 after hours.

Good luck in this rigged casino,

Geron up big

Geron up 20 cents to $2.27 on 900,000+ shares. No news, I sold the $2 Oct calls I put up 30 more at $3 Dec at 25 cents. Note that when I sold the $2 Calls a few days late it's up 20 cents. Still think we go under $2 but not till Sept and with my luck maybe not at all, which is ok I have 11,000+ shares not covered by calls.

Good luck in this rigged casino,

Geron up 1 cent

Geron closed up one cent at $2.07 on 652,263 shares. The three month avg. volume is 781,964 shares. I was surprised that Geron closed up, no news, no increase in volume, still think we go under $2.

ACTC down a little closed at 0.0770 on 3.4 million shares. The three month avg. volume is 4.9 million shares. Just waiting for more good news on Phase 1/2 trials, a new partner, reverse split and SEC settlement.

AAPL down to close at $662.63 on 14.9 million shares. The three month avg. volume is 14.2 million shares. We still will go higher.

Sept. is a bad month for stock, most of the time.

Good luck in this rigged casino,

Geron going under $2

Geron closed down 5 cents at $2.06 on 781,111 shares. The three month avg. volume is 778,302. I think we go under $2 by Friday if there is no good news. I missed out on selling Dec $3 calls. But I did sell 20 Oct $2 call for 40 cents.

ACTC closed down a little at 0.0778 on 2.3 million shares. The three month avg. volume is 5 million share. With no good news we go lower.

AAPL came back up $12.81 to close at $668.87 on 20 million shares. The three month avg. volume is 14.3 million shares. We go higher.

Good luck in this rigged casino,

Geron up on good volume

Geron closed up 4 cents at $2.11 the day range was $2.05-$2.2899. On 2.1 million shares, the three month avg. volume is 757,148 shares. Geron is having a hard time breaking out above $2.30.

ACTC down a little at 0.0785 on 2.7 million shares. The three month avg. volume is 5 million shares. We go lower with no good news.

AAPL closed down $9.09 at $656.06 on 28.7 million shares. The three month avg. volume is 14.2 million shares.  Someone with very little sense down graded AAPL. AAPL is good for $750 in 6 months.

Good luck in this rigged casino,

Geron making up for down day

Geron running up today, at $2.24 up 17 cents on great volume of 1.4 million + shares. Sold some Oct $2 and Dec $3 calls. This is a just in case things don't work out, plus I have way to many shares. All calls if called home will make me money.

Good luck in this rigged casino.

Geron couldn't make it three up days

Geron closed down 6 cents at $2.07 on 1.1 million shares. The three month avg. volume is 751.026 shares. We need real news, something like a new partner, selling the stem cell business, good results from the 6 Phase two trials.

ACTC broke below 8 cent and closed at 0.0795 on 2.9 million shares.

AAPL up big to closed at $665.15, on 21.5 million shares, note the three month avg. volume is 14.2 million shares. We go higher.

Good luck in this rigged casino,

Imetelstat in Geron trials maybe working

The stock should be moving upward on the comments from the latest conference call regarding Imetelstat.

The trials for Imetelstat are looking at Progression-free survival. They are looking at how long people are going free of new or progressing disease.

With that said the company has targets when they think they will see lung CA patients or breast CA patients disease progress. If they are meeting these target dates the results should be released when they are expected (such as Imetelstat in the lung cancer patients). However if the cancer is being held at bay there is lengthening of the progression free survival and such the data or events will cause a delay in data results such as with the breast cancer trial. [MAYBE]

All in all this trial looks to meet or beat its end points based on progression free survival and keeping data release dates on target or delaying them.

This was from Yahoo's message broad on Geron. I agree with the statement that the delay in reporting results MAYBE due the lengthening of the progression free survival of said patients. This would make Geron a $5-10 dollar, maybe more if the other Phase two trial resuults are good. Then Geron should have no problem finding a partner. With a partner we could hit $20 and with euphoria hitting the stock a run to $40 is possible. Again this can only happen if the results are good.

Good luck in this rigged casino,

Geron up again good sign

Geron closed up 10 cents at $2.13 on 1.9 million shares. The three month avg. is 732,395 share. Usual day traders like to sell off by the end of the day and avoid holding over the weekend. This is a good sign that somebody knows something or it's the Market Makers running the price up. Was not able to sell covered calls, I wanted 25 cents on the price was 20 cent for Dec 12 $3. If we get a early price move up Monday will sell a few at 25 cents. Geron rarely runs up three days in a row, we will see Monday.

ACTC barely holding 8 cents on 2.8 million shares. The three month avg. volume is 5.1 million shares. We go lower with no news.

AAPL closed up again at $648.11 on 15.6 million shares. Note that it's above the three month avg. for the first time in a while, 14.4 million shares. Good sign we go higher.

Good luck in this rigged casino,

Geron up big closed over $2

Geron closed up 32 cents at $2.03 on outstanding volume of 3.2 million shares. The three month avg. volume is 687,805 shares. This move was from the Seeking Alpha article 08-16-2012. If we can get to $2.20 Friday I was sell some cover calls for Sept. Remember Geron Phase two trials must be good or Geron share will be pennies. Three of the trials will have results in Dec 2012 and three more in the 1st and 2nd Q of 2013.

ACTC closed at 0.0808 on only 1.9 million shares. The three month avg. volume is 5.1 million shares.

AAPL up again at $636.34 on 9 million shares. The three month avg. volume is 14.6 million shares. We'll hit $700 after the I 5 phone is released.

Good luck in this rigged casino,

Buy Geron so says Seeking Alpha

Biotechnology is one of our favorite sectors, because it offers investors the opportunity to invest in companies where the fundamentals truly do matter. For development-stage companies, it is rare to see their stocks rise and fall based solely on macroeconomic headlines and rumors. And in today's volatile markets, where it seems that everything is correlated and every stock is linked, it is refreshing to see that biotechnology companies can still move to the beat of their own drum. We would like to highlight one such company. Geron (GERN) is a Menlo Park, California, biotechnology company specializing in oncology treatments. The next 12 months will be among the most important in the company's history, and for risk-tolerant investors, now is the time to buy shares

Check out the rest of the article it's long but very good. I've been saying the same thing for months.
This should take Geron to $2 if the market believes the article and in Geron.

Good luck in this rigged casino,

Still waiting on ACTC and Geron results

ACTC down a little to close at 0.0809 on 3.4 million shares. The three month avg. volume is 5.1 million shares. With no good news we break down to under 8 cents.

Geron closed the same again at $1.71 on 283,568 shares. The three month avg. volume is 687,805 shares. Just waiting for Dec 2012 and 1st and or 2nd Q 2013.

AAPL closed down a little at $630.83 on 9.2 million shares. The three month avg. volume is 14.6 million shares. Waiting for I phone 5.

Good luck in this rigged casino,

Waiting for results ACTC and Geron

ACTC closed up a little at 0.0818 on 1.8 million shares. The three month avg. volume is 5.2 million shares. Waiting for more good results on the Phase 1/2 trials.

Geron closed flat at $1.71 on 353,837 shares. The three month avg, volume is 687,556 shares. Waiting for results on 3 Phase 2 trial in Dec and 3 more Phase 2 trials in the 1st and or 2nd Q of 2013.

AAPL just keeps going up closed at $631.69 on 12 million shares. The three month avg. is 14.7 million shares.

Good luck in this rigged casino,

ACTC earnings call was good

ACTC closed down a little at 0.083 on 4.4 million shares. The three month avg. volume is 5.4 million shares.
I read the earnings call is was interesting. Still a waiting game, a partner, a SEC settlement, and more good results from Phase 1/2 trials.

Geron up one cent to closed at $1.72 on only 270,097 shares. The three month avg. volume is 700,183 shares. Same waiting game.

AAPL closed up $3.52 at $620.73 on 7.9 million shares. The three month avg. volume is 14.9 million shares.

Good luck in this rigged casino,

Geron, ACTC down just a little

Geron down 4 cents to close at $1.71 on only 431,44 shares. The three month avg. is 709,645 shares.
Waiting, waiting and waiting, buy on the dips.

ACTC closed at 0.0879 the volume was 4.4 million shares. The three month avg. is 5.4 million shares. It's waiting, waiting and waiting,  buy only if you're a true believer, on the dips

AAPL closed down $1.05 AT $619.86 on 8.6 million shares. The three month avg. is 15.2 million shares.
It's also waiting game, new phone soon, maybe Apple TV. Buy the dips.

Good luck in this rigged casino,

Waiting for results ACTC and Geron

ACTC closed at 0.0889 just under 9 cents on only 2.2 million shares. The three month avg. is 5.4 million shares.

Geron was up one whole penny, to close at $1.75 on only 462,676 shares. The three month avg. is 709,645 shares.

AAPL closed down $1.64 at $620.91 on 10.3 million shares. The three month avg. volume is 15.2 million shares.

It's just a waiting game on all three stocks. Waiting for trial results, waiting for partners, and waiting for I5 and or Apple TV. Pay the dips.

Good luck in this rigged casino,

Geron up 2 cents ACTC holds 9

Geron closed up 2 cents at $1.69 on 602,786 shares. The three month avg. is 718,260 shares. Waiting, waiting, waiting, Dec 2012 for the results of 3 Phase two trials.

ACTC closed down a little at 9 cents on 10.5 million shares. The three month avg. is 5.3 million shares. Waiting.

AAPL closed up $7.91 at $615.70 on 12.3 million shares. The three month avg. is 15.4 million shares. I think AAPL will be $750+ IN ONE YEAR.

Good luck in this rigged casino,

ACTC up to 9 big ones

That's cents, nine big cents. ACTC closed at 9 cents up over 4% on 8.5 million shares. The three month avg. volume is 5.2 million shares. All the news on the Phase 1/2 trials have been positive, we should slowly move higher. Still need the reverse split, the listing to the big broad, the SEC lawsuit settled, and most important a partner with lots of money. Hopefully not a China partner.

Geron closed up 2 cents  at $1.67 on 638,521 shares. The three month avg, is 718,260 shares. Just waiting till Dec 2012 with three Phase two trials results coming.

AAPL closed up 98 cents at $607.79 on 11.9 million shares. The three month avg volume is 15.4 million shares.

Good luck in this rigged casino,

ACTC up on Gary Rabin's interview

ACTC closed up at 0.0869 on 6.5 million shares. The three month avg. volume 5.2 million shares.
This story below is great. You can find the rest of the article on Zoomed In.

I’m in the ACT Stem Cell Trial for Stargardt Disease!

by Maurie Hill on July 31, 2012

iMy last article highlighted my experience at the Visions 2012 conference and the closing session’s three main speakers. They spoke about some of the ongoing human clinical trials exhibiting great promise for battling retinal degenerative diseases. One of those speakers, Matthew Vincent, Director of Business Development at Advanced Cell Technology (ACT), spoke effectively about the current stem cell trials for both Stargardt disease and AMD. And even more recently, ACT announced that they treated their fourth Stargardt patient, the first patient to receive a higher RPE cell concentration in their worst eye. I am excited to inform you that I am this patient! I was treated on July 11^th at Wills Eye Institute in Philadelphia. It was an exciting experience that I’ll never forget; physically joining the team within the many teams that have worked so hard to bring us to this point in medical history

Geron is down again closing at $1.65 on 800,758 shares. The three month avg. is 712,632 shares. Waiting for results in Dec 2012.

AAPL, I was feeling great pre-market. AAPL $6+ should have sold. Closed down $3.95 at $616.81.

Good luck in this rigged casino,